Shares of Zura Bio Limited (NASDAQ:ZURA – Get Free Report) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.75.
ZURA has been the topic of a number of recent analyst reports. Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Chardan Capital lifted their target price on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th.
View Our Latest Stock Analysis on Zura Bio
Institutional Investors Weigh In On Zura Bio
Zura Bio Trading Up 4.5%
Shares of Zura Bio stock opened at $3.69 on Wednesday. Zura Bio has a 12-month low of $1.00 and a 12-month high of $7.44. The company has a market cap of $350.11 million, a price-to-earnings ratio of -3.39 and a beta of 0.03. The company’s 50-day moving average price is $4.94 and its 200-day moving average price is $5.23.
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, sell-side analysts predict that Zura Bio will post -0.76 earnings per share for the current year.
About Zura Bio
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
See Also
- Five stocks we like better than Zura Bio
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
